“Phenomenal”: Merck’s new COVID therapeutic may be a gamechanger HotAir

Merck has been notably absent from America s vaccine offensive against the virus, having seen its vaccine candidate go bust in trials earlier this year. But its effort to nuke the virus on the back end, after someone is already infected with it, looks like a smash success based on the data it released this morning. It partnered with a firm called Ridgeback Biotherapeutics to develop an antiviral called molnupiravir. An antiviral to treat COVID already exists, of course: That s remdesivir, which was authorized for emergency use many months ago. But remdesivir s effect on the progression of the disease is modest and it needs to be administered by a medical tech via IV.

Molnupiravir is a pill. And its effect isn t so modest.

via hotair.com

Good news.